Asfotase alfa, a recombinant form of TNAP (sALP‐Fc‐D10) that contains the Fc region of immunoglobulin (Fc) and a deca‐aspartate (D10) mineral‐targeting motif(18) was shown efficacious in extending life and preventing skeletal and dental disease in a mouse model of severe infantile HPP.(18, 19, 20, 21, 22) These studies led to clinical trials in infants and young children with perinatal/infantile HPP,(23) and this biologic was subsequently approved in 2015 as an enzyme replacement therapy (ERT) for pediatric‐onset HPP in the US and Europe and regardless of age of onset in Japan. The gene discussed is ALPL; the disease is hypophosphatasia.